Markers of cell proliferation as prognostic factors in differentiated thyroid cancer

F. Basolo, L. Fugazzola, G. Fontanini, R. Elisei, S. Pepe, G. Bevilacqua, A. Pinchera, F. Pacini

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Age is the most accepted prognostic factor in differentiated thyroid cancer. Other parameters, such as tumor size, grading, extrathyroidal extension, have also been associated with the prognosis of these tumors. Since the identification of reliable prognostic factors is essential to avoid unnecessary aggressive treatment for a disease, such as thyroid carcinoma, which only rarely is fatal, we studied two indices of cell proliferation in patients with differentiated thyroid cancer, in relation to their outcome. We studied two groups of patients with differentiated thyroid cancer, selected in a way to have one group (33 patients) with a good outcome and one (16 patients) with a fatal outcome, after a follow-up of at least 5 years. By immunohistochemistry the primary tumors of all patients were analyzed for the expression of the proliferating cell nuclear antigen (PCNA)/cyclin. In 38 (77.5%) of them also the nuclear DNA content and the percentages of S-phases were analyzed by flow cytometric analysis. At diagnosis the two groups of patients differed significantly with regard to age and extrathyroidal extension, but not for tumor size and grading. A significant difference (p=0.02) was found in the positivity of PCNA/cyclin expression between the fatal outcome group (66.6%) and the surviving patients (27%), and in the percentage of cells in the S-phase, 16.4±7.7% in the fatal outcome group patients and 6.0±2.6% in the surviving patients (p=0.0001). No difference was found in the nuclear DNA content of the two groups. A positive correlation was found between PCNA expression and S-phase (r(s)=0.55; p

Original languageEnglish
Pages (from-to)1077-1081
Number of pages5
JournalInternational Journal of Oncology
Volume3
Issue number6
Publication statusPublished - 1993

Fingerprint

Thyroid Neoplasms
Cell Proliferation
Fatal Outcome
Proliferating Cell Nuclear Antigen
S Phase
Cyclins
Neoplasm Grading
DNA
Neoplasms
Immunohistochemistry

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Basolo, F., Fugazzola, L., Fontanini, G., Elisei, R., Pepe, S., Bevilacqua, G., ... Pacini, F. (1993). Markers of cell proliferation as prognostic factors in differentiated thyroid cancer. International Journal of Oncology, 3(6), 1077-1081.

Markers of cell proliferation as prognostic factors in differentiated thyroid cancer. / Basolo, F.; Fugazzola, L.; Fontanini, G.; Elisei, R.; Pepe, S.; Bevilacqua, G.; Pinchera, A.; Pacini, F.

In: International Journal of Oncology, Vol. 3, No. 6, 1993, p. 1077-1081.

Research output: Contribution to journalArticle

Basolo, F, Fugazzola, L, Fontanini, G, Elisei, R, Pepe, S, Bevilacqua, G, Pinchera, A & Pacini, F 1993, 'Markers of cell proliferation as prognostic factors in differentiated thyroid cancer', International Journal of Oncology, vol. 3, no. 6, pp. 1077-1081.
Basolo F, Fugazzola L, Fontanini G, Elisei R, Pepe S, Bevilacqua G et al. Markers of cell proliferation as prognostic factors in differentiated thyroid cancer. International Journal of Oncology. 1993;3(6):1077-1081.
Basolo, F. ; Fugazzola, L. ; Fontanini, G. ; Elisei, R. ; Pepe, S. ; Bevilacqua, G. ; Pinchera, A. ; Pacini, F. / Markers of cell proliferation as prognostic factors in differentiated thyroid cancer. In: International Journal of Oncology. 1993 ; Vol. 3, No. 6. pp. 1077-1081.
@article{b2bd8b31d7a64d1fb347ac21bd9eef05,
title = "Markers of cell proliferation as prognostic factors in differentiated thyroid cancer",
abstract = "Age is the most accepted prognostic factor in differentiated thyroid cancer. Other parameters, such as tumor size, grading, extrathyroidal extension, have also been associated with the prognosis of these tumors. Since the identification of reliable prognostic factors is essential to avoid unnecessary aggressive treatment for a disease, such as thyroid carcinoma, which only rarely is fatal, we studied two indices of cell proliferation in patients with differentiated thyroid cancer, in relation to their outcome. We studied two groups of patients with differentiated thyroid cancer, selected in a way to have one group (33 patients) with a good outcome and one (16 patients) with a fatal outcome, after a follow-up of at least 5 years. By immunohistochemistry the primary tumors of all patients were analyzed for the expression of the proliferating cell nuclear antigen (PCNA)/cyclin. In 38 (77.5{\%}) of them also the nuclear DNA content and the percentages of S-phases were analyzed by flow cytometric analysis. At diagnosis the two groups of patients differed significantly with regard to age and extrathyroidal extension, but not for tumor size and grading. A significant difference (p=0.02) was found in the positivity of PCNA/cyclin expression between the fatal outcome group (66.6{\%}) and the surviving patients (27{\%}), and in the percentage of cells in the S-phase, 16.4±7.7{\%} in the fatal outcome group patients and 6.0±2.6{\%} in the surviving patients (p=0.0001). No difference was found in the nuclear DNA content of the two groups. A positive correlation was found between PCNA expression and S-phase (r(s)=0.55; p",
author = "F. Basolo and L. Fugazzola and G. Fontanini and R. Elisei and S. Pepe and G. Bevilacqua and A. Pinchera and F. Pacini",
year = "1993",
language = "English",
volume = "3",
pages = "1077--1081",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "6",

}

TY - JOUR

T1 - Markers of cell proliferation as prognostic factors in differentiated thyroid cancer

AU - Basolo, F.

AU - Fugazzola, L.

AU - Fontanini, G.

AU - Elisei, R.

AU - Pepe, S.

AU - Bevilacqua, G.

AU - Pinchera, A.

AU - Pacini, F.

PY - 1993

Y1 - 1993

N2 - Age is the most accepted prognostic factor in differentiated thyroid cancer. Other parameters, such as tumor size, grading, extrathyroidal extension, have also been associated with the prognosis of these tumors. Since the identification of reliable prognostic factors is essential to avoid unnecessary aggressive treatment for a disease, such as thyroid carcinoma, which only rarely is fatal, we studied two indices of cell proliferation in patients with differentiated thyroid cancer, in relation to their outcome. We studied two groups of patients with differentiated thyroid cancer, selected in a way to have one group (33 patients) with a good outcome and one (16 patients) with a fatal outcome, after a follow-up of at least 5 years. By immunohistochemistry the primary tumors of all patients were analyzed for the expression of the proliferating cell nuclear antigen (PCNA)/cyclin. In 38 (77.5%) of them also the nuclear DNA content and the percentages of S-phases were analyzed by flow cytometric analysis. At diagnosis the two groups of patients differed significantly with regard to age and extrathyroidal extension, but not for tumor size and grading. A significant difference (p=0.02) was found in the positivity of PCNA/cyclin expression between the fatal outcome group (66.6%) and the surviving patients (27%), and in the percentage of cells in the S-phase, 16.4±7.7% in the fatal outcome group patients and 6.0±2.6% in the surviving patients (p=0.0001). No difference was found in the nuclear DNA content of the two groups. A positive correlation was found between PCNA expression and S-phase (r(s)=0.55; p

AB - Age is the most accepted prognostic factor in differentiated thyroid cancer. Other parameters, such as tumor size, grading, extrathyroidal extension, have also been associated with the prognosis of these tumors. Since the identification of reliable prognostic factors is essential to avoid unnecessary aggressive treatment for a disease, such as thyroid carcinoma, which only rarely is fatal, we studied two indices of cell proliferation in patients with differentiated thyroid cancer, in relation to their outcome. We studied two groups of patients with differentiated thyroid cancer, selected in a way to have one group (33 patients) with a good outcome and one (16 patients) with a fatal outcome, after a follow-up of at least 5 years. By immunohistochemistry the primary tumors of all patients were analyzed for the expression of the proliferating cell nuclear antigen (PCNA)/cyclin. In 38 (77.5%) of them also the nuclear DNA content and the percentages of S-phases were analyzed by flow cytometric analysis. At diagnosis the two groups of patients differed significantly with regard to age and extrathyroidal extension, but not for tumor size and grading. A significant difference (p=0.02) was found in the positivity of PCNA/cyclin expression between the fatal outcome group (66.6%) and the surviving patients (27%), and in the percentage of cells in the S-phase, 16.4±7.7% in the fatal outcome group patients and 6.0±2.6% in the surviving patients (p=0.0001). No difference was found in the nuclear DNA content of the two groups. A positive correlation was found between PCNA expression and S-phase (r(s)=0.55; p

UR - http://www.scopus.com/inward/record.url?scp=0027494551&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027494551&partnerID=8YFLogxK

M3 - Article

VL - 3

SP - 1077

EP - 1081

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 6

ER -